Online inquiry

IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1322MR)

This product GTTS-WQ1322MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MET gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000245.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4233
UniProt ID P08581
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ1322MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7880MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ4913MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ8867MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ11460MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ9757MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JS001
GTTS-WQ2614MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 557
GTTS-WQ15798MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ13941MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-2810
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW